Britannia Industries
Transcription
Britannia Industries
Company Update INDIA CONSUMER STAPLES 7 January 2015 BUY Britannia Industries TP: INR 2,200.00 10.2% BRIT IN Outlook strong; raising earnings/TP – maintain BUY We raise our FY16/FY17 earnings for BRIT by ~13%/14% on expectations of continued benefits flowing in from mix improvements, cost synergies and a muted RM inflation outlook. We built in a 350bps margin expansion over FY14-FY17, leading to a strong EBITDA/PAT CAGR of 29% over this period. An increase in A&P spends in H2FY15/FY16 should lead to market share gains, while margins could surprise on lower RM costs. We roll over to a Mar’16 TP of Rs 2,200 (from Rs 1,800 earlier) and maintain BUY on the stock. REPORT AUTHORS Gaurang Kakkad +91 22 6766 3470 gaurang.kakkad@religare.com Topline growth at 14.6% CAGR: We expect BRIT to report a 14.6% revenue CAGR over FY14-FY17 with volume growth likely to average at ~7-8%. We expect the company to continue benefiting from the premiumisation of its portfolio, with premium-end offerings likely to see a higher growth rate (20% YoY) than the lower end segment. Despite a benign input cost scenario (flattish RM cost Index YoY), the company is likely to take 2-3% price hikes each year as competitive intensity in the sector has remained muted. Premal Kamdar Margins to expand 350bps over FY14-FY17: We expect BRIT to report a 29% EBITDA CAGR over FY14-FY17 as margins likely improve from ~8% in FY14 to ~11.5% in FY17. A richer product mix coupled with a benign input cost scenario would shore up gross margins by 300bps over FY14-FY17, while the company also benefits from operating leverage due to cost rationalisation measures. BRIT is also likely to increase A&P spends from 8.3% in FY15 to 8.9% in FY17 as it tries to gain back market share from competitors. We expect a 29% PAT CAGR over FY14-FY17 on the back of strong margins. INR 1,995.75 Upgrading earnings; TP revised to Rs 2,200: We raise our FY16/FY17 earnings for BRIT by ~13%/14% on expectations of strong margins due to premiumisation benefits, benign input costs and operating leverage. We roll over to a Mar’16 TP of Rs 2,200 (from a Dec’15 TP of Rs 1,800). Maintain BUY. 3M AVG DAILY VOLUME/VALUE +91 22 6766 3469 premal.kamdar@religare.com PRICE CLOSE (07 Jan 15) MARKET CAP INR 239.3 bln USD 3.8 bln SHARES O/S 119.5 mln FREE FLOAT 49.0% 0.1 mln / USD 3.8 mln 52 WK HIGH 52 WK LOW INR 1,926.95 INR 809.10 Financial Highlights Y/E 31 Mar FY13A FY14A FY15E FY16E FY17E Revenue (INR mln) 61,359 68,293 78,358 89,706 1,02,738 EBITDA (INR mln) 3,710 5,438 7,817 9,885 11,776 Adjusted net profit (INR mln) 2,595 3,956 5,581 7,058 8,413 Adjusted EPS (INR) 21.7 33.0 46.5 58.8 70.1 Adjusted EPS growth (%) 29.9 51.8 41.1 26.5 19.2 DPS (INR) 7.1 10.7 15.4 19.5 23.3 ROIC (%) 43.6 45.2 68.2 97.5 132.8 Adjusted ROAE (%) 53.7 58.4 59.0 55.0 49.7 Adjusted P/E (x) 91.9 60.5 42.9 33.9 28.5 EV/EBITDA (x) 64.6 44.3 30.6 23.9 19.7 P/BV (x) 42.7 30.0 21.9 16.3 12.5 (INR) Stock Price Index Price 29,400 1,790 1,290 24,400 790 19,400 290 14,400 Source: Company, Bloomberg, RCML Research This report has been prepared by Religare Capital Markets Limited or one of its affiliates. For analyst certification and other important disclosures, please refer to the Disclosure and Disclaimer section at the end of this report. Analysts employed by non-US affiliates are not registered with FINRA regulation and may not be subject to FINRA/NYSE restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account. BUY Britannia Industries TP: INR 2,200.00 10.2% BRIT IN Company Update INDIA CONSUMER STAPLES Per Share Data Y/E 31 Mar (INR) FY13A FY14A FY15E FY16E FY17E Reported EPS 21.7 33.0 46.5 58.8 70.1 Adjusted EPS 21.7 33.0 46.5 58.8 70.1 7.1 10.7 15.4 19.5 23.3 46.7 66.5 91.3 122.6 159.9 FY13A FY14A FY15E FY16E FY17E 3.9 3.5 3.0 2.6 2.3 EV/EBITDA 64.6 44.3 30.6 23.9 19.7 Adjusted P/E 91.9 60.5 42.9 33.9 28.5 P/BV 42.7 30.0 21.9 16.3 12.5 FY13A FY14A FY15E FY16E FY17E EBITDA margin 6.0 8.0 10.0 11.0 11.5 EBIT margin 4.9 6.7 8.7 9.8 10.3 Adjusted profit margin 4.2 5.8 7.1 7.9 8.2 Adjusted ROAE 53.7 58.4 59.0 55.0 49.7 ROCE 28.6 33.9 42.1 41.8 39.1 Revenue 12.4 11.3 14.7 14.5 14.5 EBITDA 29.6 46.6 43.8 26.4 19.1 Adjusted EPS 29.9 51.8 41.1 26.5 19.2 153.3 (0.3) (5.1) (14.9) (8.0) DPS BVPS Valuation Ratios Y/E 31 Mar (x) EV/Sales Financial Ratios Y/E 31 Mar Profitability & Return Ratios (%) YoY Growth (%) Invested capital Working Capital & Liquidity Ratios Receivables (days) Inventory (days) 7 6 6 6 6 38 35 35 35 35 Payables (days) 53 43 44 44 43 Current ratio (x) 0.9 0.8 1.0 1.2 1.4 Quick ratio (x) 0.1 0.1 0.3 0.5 0.7 Gross asset turnover 4.7 4.6 4.6 4.9 5.1 Total asset turnover 3.3 3.4 3.3 3.0 2.9 Net interest coverage ratio 7.2 55.6 136.3 195.4 318.2 Adjusted debt/equity 0.5 0.1 (0.2) (0.5) (0.6) FY13A FY14A FY15E FY16E FY17E 72.4 69.5 69.0 69.0 69.0 120.3 123.6 118.7 116.3 115.4 Turnover & Leverage Ratios (x) DuPont Analysis Y/E 31 Mar (%) Tax burden (Net income/PBT) Interest burden (PBT/EBIT) EBIT margin (EBIT/Revenue) 4.9 6.7 8.7 9.8 10.3 Asset turnover (Revenue/Avg TA) 330.9 339.8 327.2 304.1 285.1 Leverage (Avg TA/Avg equities) 383.6 296.5 253.0 229.9 212.7 53.7 58.4 59.0 55.0 49.7 Adjusted ROAE 7 January 2015 Page 2 of 4 BUY Britannia Industries TP: INR 2,200.00 10.2% BRIT IN Company Update INDIA CONSUMER STAPLES Income Statement Y/E 31 Mar (INR mln) FY13A FY14A FY15E FY16E FY17E Total revenue 61,359 68,293 78,358 89,706 1,02,738 EBITDA 3,710 5,438 7,817 9,885 11,776 EBIT 2,979 4,606 6,816 8,793 10,568 Net interest income/(expenses) (413) (83) (50) (45) (33) Other income/(expenses) 1,017 1,170 1,322 1,481 1,658 Exceptional items 0 0 0 0 0 EBT 3,583 5,693 8,088 10,229 12,193 Income taxes (986) (1,736) (2,507) (3,171) (3,780) 0 0 0 0 0 (2) (2) 0 0 0 2,595 3,956 5,581 7,058 8,413 Extraordinary items Min. int./Inc. from associates Reported net profit Adjustments 0 0 0 0 0 2,595 3,956 5,581 7,058 8,413 FY13A FY14A FY15E FY16E FY17E 6,749 7,982 9,061 10,132 11,448 0 0 0 0 0 Provisions 2,786 3,321 4,853 6,137 7,316 Debt funds 3,610 1,672 1,672 1,672 1,672 0 0 0 0 0 239 240 240 240 240 Reserves & surplus 5,339 7,741 10,710 14,465 18,941 Shareholders' fund 5,578 7,981 10,950 14,705 19,181 18,745 20,980 26,560 32,670 39,640 Cash and cash eq. 1,029 1,091 3,825 8,582 13,513 Accounts receivables 1,228 1,087 1,288 1,451 1,675 Inventories 3,747 4,203 4,789 5,356 6,051 Other current assets 2,905 3,163 3,643 4,135 4,729 Investments 1,082 1,979 1,979 1,979 1,979 Net fixed assets 7,368 8,543 9,527 9,660 10,185 CWIP 1,473 1,473 1,473 1,473 1,473 0 0 0 0 0 (86) (86) (86) (86) (86) Adjusted net profit Balance Sheet Y/E 31 Mar (INR mln) Accounts payables Other current liabilities Other liabilities Equity capital Total liabilities and equities Intangible assets Deferred tax assets, net Other assets 0 0 0 0 0 Total assets 18,746 21,452 26,439 32,549 39,519 FY13A FY14A FY15E FY16E FY17E 3,327 4,788 6,582 8,149 9,622 413 83 50 45 33 0 0 0 0 0 (158) 1,194 1,343 1,135 981 Cash Flow Statement Y/E 31 Mar (INR mln) Net income + Depreciation Interest expenses Non-cash adjustments Changes in working capital Other operating cash flows 30 84 192 45 33 3,612 6,149 8,167 9,374 10,669 (2,154) (2,007) (1,985) (1,225) (1,733) 2,150 (897) 0 0 0 Other investing cash flows 286 0 0 0 0 Cash flow from investing 282 (2,904) (1,985) (1,225) (1,733) 0 Cash flow from operations Capital expenditures Change in investments Equities issued 0 (4) 0 0 Debt raised/repaid (2,268) (1,938) 0 0 0 Interest expenses (413) (83) (50) (45) (33) (3,937) Dividends paid (1,189) (1,811) (2,612) (3,303) Other financing cash flows (423) (83) (50) (45) (33) Cash flow from financing (4,293) (3,919) (2,712) (3,393) (4,004) Changes in cash and cash eq (399) (674) 3,470 4,756 4,932 Closing cash and cash eq 1,029 355 3,825 8,582 13,513 7 January 2015 Page 3 of 4 RESEARCH DISCLAIMER Important Disclosures This report was prepared, approved, published and distributed by a Religare Capital Markets (“RCM”) group company located outside of the United States (a “non-US Group Company”). This report is distributed in the U.S. by Enclave Capital LLC (“Enclave Capital”), a U.S. registered broker dealer, on behalf of RCM only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the “Exchange Act”)) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital. Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. (“FINRA”) or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization. Subject to any applicable laws and regulations at any given time, non-US Group Companies, their affiliates or companies or individuals connected with RCM (together, “Connected Companies”) may make investment decisions that are inconsistent with the recommendations or views expressed in this report and may have long or short positions in, may from time to time purchase or sell (as principal or agent) or have a material interest in any of the securities mentioned or related securities or may have or have had a business or financial relationship with, or may provide or have provided investment banking, capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. Any particular arrangements or relationships are disclosed below. As a result, recipients of this report should be aware that Connected Companies may have a conflict of interest that could affect the objectivity of this report. See “Special Disclosures” for certain additional disclosure statements, if applicable. This report is only for distribution to investment professionals and institutional investors. Analyst Certification Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. Analysts and strategists are paid in part by reference to the profitability of RCM. Stock Ratings are defined as follows Recommendation Interpretation (Recommendation structure changed with effect from March 1, 2009) Recommendation Buy Hold Sell Expected absolute returns (%) over 12 months More than 15% Between 15% and –5% Less than –5% Expected absolute returns are based on the share price at market close unless otherwise stated. Stock recommendations are based on absolute upside (downside) and have a 12-month horizon. Our target price represents the fair value of the stock based upon the analyst’s discretion. We note that future price fluctuations could lead to a temporary mismatch between upside/downside for a stock and our recommendation. Stock Ratings Distribution As of 1 January 2015, out of 194 rated stocks in the RCM coverage universe, 109 have BUY ratings (including 7 that have been investment banking clients in the last 12 months), 59 are rated HOLD and 26 are rated SELL. Research Conflict Management Policy RCM research has been published in accordance with our conflict management policy, which is available here. Disclaimers This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject RCM to any registration or licensing requirement within such jurisdiction(s). This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to RCM. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of RCM. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of RCM or its affiliates, unless specifically mentioned otherwise. not treat recipients as its customers by virtue of their receiving the report. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. In addition, nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal recommendation to you. Information and opinions presented in this report were obtained or derived from sources that RCM believes to be reliable, but RCM makes no representations or warranty, express or implied, as to their accuracy or completeness or correctness. RCM accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to RCM. This report is not to be relied upon in substitution for the exercise of independent judgment. RCM may have issued, and may in the future issue, a trading call regarding this security. Trading calls are short term trading opportunities based on market events and catalysts, while stock ratings reflect investment recommendations based on expected absolute return over a 12-month period as defined in the disclosure section. Because trading calls and stock ratings reflect different assumptions and analytical methods, trading calls may differ directionally from the stock rating. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment of its original date of publication by RCM and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Investors in securities such as ADR’s, the values of which are influenced by currency volatility, effectively assume this risk. This report is distributed in India by Religare Capital Markets Limited, which is a registered intermediary regulated by the Securities and Exchange Board of India. In Dubai, it is being distributed by Religare Capital Markets (Hong Kong) Limited (Dubai Branch) which is licensed and regulated by the Dubai Financial Services Authority. In Singapore, it is being distributed (i) by Religare Capital Markets (Singapore) Pte. Limited (“RCMS”) (Co. Reg. No. 200902065N) which is a holder of a capital markets services licence and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as ““institutional investors” or “accredited investors” as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore (the “SFA”). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations (the “FAR”), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to RCMS when providing any financial advisory service to an accredited investor, or “overseas investor” (as defined in regulation 36 of the FAR). Persons in Singapore should contact RCMS in respect of any matters arising from, or in connection with this publication/communication. In Hong Kong, it is being distributed by Religare Capital Markets (Hong Kong) Limited (“RCM HK”), which is licensed and regulated by the Securities and Futures Commission, Hong Kong. In Australia, it is being distributed by RCMHK which is approved under ASIC Class Orders. In Sri Lanka, it is being distributed by Bartleet Mallory Stockbrokers, which is licensed under Securities and Exchange Commission of Sri Lanka. If you wish to enter into a transaction please contact the RCM entity in your home jurisdiction unless governing law provides otherwise. In jurisdictions where RCM is not registered or licensed to trade in securities, transactions will only be effected in accordance with applicable securities legislation which may vary from one jurisdiction to another and may require that the trade be made in accordance with applicable exemptions from registration or licensing requirements. Religare Capital Markets does and seeks to do business with companies covered in our research report. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of research produced by Religare Capital Markets. Investors should consider our research as only a single factor in making their investment decision. Any reference to a third party research material or any other report contained in this report represents the respective research organization's estimates and views and does not represent the views of RCM and RCM, its officers, employees do not accept any liability or responsibility whatsoever with respect to its accuracy or correctness and RCM has included such reports or made reference to such reports in good faith. This report may provide the addresses of, or contain hyperlinks to websites. Except to the extent to which the report refers to material on RCM’s own website, RCM takes no responsibility whatsoever for the contents therein. Such addresses or hyperlinks (including addresses or hyperlinks to RCM’s own website material) is provided solely for your convenience and information and the content of the linked site does not in any way form part of this report. Accessing such website or following such link through this report or RCM’s website shall be at your own risk. Special Disclosures (if applicable) Not Applicable The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. RCM has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. RCM will 7 January 2015 Page 4 of 4